KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
- University of Helsinki, Finland
- Max Planck Institute for Heart and Lung Research, Germany
- Wihuri Research Institute, Finland
- Cited 0
- Views 1,341
- Annotations
Abstract
Vascular endothelial growth factor-C (VEGF-C) acts primarily on endothelial cells, but also on non-vascular targets, e.g. in the CNS and immune system. Here we describe a novel, unique VEGF-C form in the human reproductive system produced via cleavage by kallikrein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA). KLK3 activated VEGF-C specifically and efficiently through cleavage at a novel N-terminal site. We detected VEGF-C in seminal plasma, and sperm liquefaction occurred concurrently with VEGF-C activation, which was enhanced by collagen and calcium binding EGF domains 1 (CCBE1). After plasmin and ADAMTS3, KLK3 is the third protease shown to activate VEGF-C. Since differently activated VEGF-Cs are characterized by successively shorter N-terminal helices, we created an even shorter hypothetical form, which showed preferential binding to VEGFR-3. Using mass spectrometric analysis of the isolated VEGF-C-cleaving activity from human saliva, we identified cathepsin D as a protease that can activate VEGF-C as well as VEGF-D.
Article and author information
Author details
Funding
Academy of Finland (265982)
- Michael Jeltsch
European Research Council (Horizon 2020 Research and Innovation programme 743155)
- Kari Alitalo
Wihuri Research Institute
- Kari Alitalo
Academy of Finland Centre of Excellence Program 2014-2019 (307366)
- Kari Alitalo
Novo Nordisk Foundation
- Kari Alitalo
Cancer Society of Finland
- Sawan Kumar Jha
Biomedicum Helsinki-säätiö
- Sawan Kumar Jha
Päivikki and Sakari Sohlberg Foundation
- Khushbu Rauniyar
Wihuri Research Institute
- Sawan Kumar Jha
Academy of Finland (272683)
- Michael Jeltsch
Academy of Finland (273612)
- Michael Jeltsch
Finnish Foundation for Cardiovascular Research
- Michael Jeltsch
Academy of Finland (273817)
- Michael Jeltsch
Jane ja Aatos Erkon Säätiö
- Michael Jeltsch
Cancer Society of Finland
- Michael Jeltsch
Magnus Ehrnroothin Säätiö
- Michael Jeltsch
K Albin Johansson Foundation
- Michael Jeltsch
Integrated Life Science Doctoral Program
- Sawan Kumar Jha
Sigrid Jusélius Foundation
- Hannu Koistinen
Laboratoriolääketieteen edistämissäätiö
- Hannu Koistinen
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments carried out in this study were performed according to guidelines and regulations approved by the National Board for Animal Experiments of the Provincial State Office of Southern Finland (ESAVI/7012/04.10.07/2016).
Reviewing Editor
- Gou Young Koh, Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST), Korea (South), Republic of
Publication history
- Received: January 2, 2019
- Accepted: May 16, 2019
- Accepted Manuscript published: May 17, 2019 (version 1)
- Version of Record published: June 21, 2019 (version 2)
Copyright
© 2019, Jha et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,341
- Page views
-
- 161
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Further reading
-
- Cancer Biology
- Cell Biology
-
- Cancer Biology
